ArticleMedical science monitor : international medical journal of experimental and clinical research2015
Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Research progress of MicroRNA in lung cancer.Discover oncology · 2026Review
- Investigating miR-30a's tumor suppressor role and its targets (MYBL2, TWF1, GALNT7, PFN2) as prognostic biomarkers in lung adenocarcinoma.Biochemistry and biophysics reports · 2025Article
- Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas.Science advances · 2023Article
- EpiMix: an integrative tool for epigenomic subtyping using DNA methylation.bioRxiv : the preprint server for biology · 2023Article
- Article
- Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.Scientific reports · 2021Article
- Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer.PeerJ · 2021Article
- Diagnostic value and prognostic significance of LI-cadherin and miR-378e in colorectal cancer.Oncology letters · 2020Article
- miR-30a regulates γ-globin expression in erythoid precursors of intermedia thalassemia through targeting BCL11A.Molecular biology reports · 2020Article
- RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome.Blood cancer journal · 2020Article
- Expression and potential prognostic value of histone family gene signature in breast cancer.Experimental and therapeutic medicine · 2019Article
- miR-30a regulates the proliferation and invasion of breast cancer cells by targeting Snail.Oncology letters · 2019Article
- Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.International journal of oncology · 2018Article
- MicroRNA-30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9.Oncology letters · 2018Article
- Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population.BMC genomics · 2018Article
- A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.Oncology letters · 2018Article
- Low expression ofBioscience reports · 2018Article
- miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study.Cancer biomarkers : section A of Disease markers · 2018Article
- MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer.Journal of oncology · 2018Review
- A qRT-PCR and Gene Functional Enrichment Study Focused on Downregulation of miR-141-3p in Hepatocellular Carcinoma and Its Clinicopathological Significance.Technology in cancer research & treatment · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent reports have suggested that miR-30a plays a tumor-suppressive role in various cancers. However, miR-30a has not been completely studied in non-small lung cancer (NSCLC). Thus, the aim of the present study was to clarify the association between the expression of miR-30a and the clinicopathological features in NSCLC patients. MATERIAL AND
methodsTotal RNA of miR-30a was extracted from 125 pairs of NSCLC patients (male 75, female 50) and their matching normal tissues. The miR-30a level was detected by using quantitative real-time polymerase chain reaction (qRT-PCR). Simultaneously, the 2-ΔCq method was used to calculate the correlation between miR-30a expression and the clinicopathological parameters and prognosis of NSCLC patients.
resultsMiR-30a expression was significantly down-regulated in NSCLC tissues (4.0696±2.4178) compared to their non-tumor lung tissues (7.4530±3.0561, P<0.001). Level of miR-30a was negatively correlated to tumor size (r=-0.197, P=0.028), lymphatic metastasis (r=-0.312, P<0.001), clinical TNM stage (r=-0.299, P=0.001), pathological grading (I/II vs. III, r=-0.224, P=0.001), and histological classification (r=-0.299, P=0.001). Survival time was 3.23±2.18 months in the low miR-30a expression group, remarkably shorter than that of the high expression group (20.72±11.63 months, P<0.001).
conclusionsMiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.